Author Index

VOLUME 21, 2001

Angulo, P, 81
Arthur, MJP, 373

Bataller, R, 437
Beavers, KL, 161
Benyon, C, 373
Berk, PD, 119
Berman, R, 115
Berson, A, 57
Blachar, A, 135
Bodenheimer, HC, Jr., 115
Brancatelli, G, 237
Brenner, DA, 437
Brunt, EM, 3, 453
Bull, LN, 535
Burns, PN, 147

Chitturi, S, 27
Clavien, P-A, 105

Di Bisceglie, AM, 453
Diehl, AM, 89
Dodd, GD, III, 283

Emre, S, 573
Eng, F, 385

Falck-Ytter, Y, 17
Farrell, GC, 27
Federle, MP, 133, 135, 237
Feranchak, AP, 469, 471
Freeze, HH, 501
Friedman, SL, 307, 385
Fromenty, B, 57

Geerts, A, 311
Gores, GJ, 1
Grompe, M, 563

Hahn, EG, 351
Houwen, R, 535

Iredale, JP, 427

Jacquemin, E, 563

Kamel, IR, 271
Klion, FM, 297, 579
Klomp, LWJ, 535
Koteish, A, 89
Kruskal, JB, 271
Kuni, CC, 179

Leyendecker, JR, 283
Lin, EC, 179
Lindor, KD, 1, 81

Mack, C, 517
Maher, JJ, 417
Mansouri, A, 57
Marchesini, G, 17
Marra, F, 397
McCullough, AJ, 17
Mendelson, DS, 293
Mochizuki, K, 213
Mortele, KJ, 195
Murakami, T, 213

Nakamura, H, 213

Paulson, EK, 225
Pessayre, D, 57
Picolli, DA, 525
Pinzani, M, 397

Rao, MS, 43
Raptopoulos, V, 271
Reddy, JK, 43
Rinaldo, P, 489
Rockey, DC, 337
Ros, PR, 195
Rosen, MA, 71
Rosencrantz, R, 573
Ruehl, M, 351

Saxena, R, 119
Schuppan, D, 351
Selzner, M, 105
Semelka, RC, 161
Shetty, K, 119
Shneider, B, 573
Siegel, MJ, 251
Siegelman, ES, 71
Sigal, SH, 115
Simpson, W, 293
Sokol, RJ, 469, 471, 517
Somasundaram, R, 351
Spinner, NB, 525
Strautnieks, S, 545
Suarez, AA, 453
Suriawinata, A, 573

Thompson, R, 545
Thung, SN, 115, 573
van Mil, SWC, 535

Yeh, HC, 293

Younossi, ZM, 17

Wasserman, JM, 115
Wilson, SR, 147

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Subject Index

VOLUME 21, 2001

A
Abetalipoproteinemia, steatohepatitis in, 27–41
Abscess, hepatic
  magnetic resonance imaging of, 161–177
  in pediatric patient, imaging of, 251–269
Acquired immunodeficiency syndrome (AIDS), in pediatric patient, hepatic imaging in, 251–269
Adenoma, hepatocellular, imaging of, 161–177, 237–249
  in pediatric patient, 251–269
Adenomatosis, liver, progesterone and, 453–459
Alagille syndrome
  clinical manifestations of, 525–534
  genetics of, 525–534
  JAG1 mutations in, 525–534
Alcohol
  liver disease caused by, clinical manifestations of, 119–128
  steatohepatitis caused by
    animal models of, 89–104
    pathophysiology of, 57–69
Alcohol use, screening tests for, 17–26
Amiodarone, steatohepatitis caused by, 27–41, 57–69
Amyloidosis, hepatic imaging in, 195–212
Angiotensin-II, in hepatic stellate cell biology, 397–416
Apoptosis, hepatic stellate cell, 427–436
ATP8B1 gene, mutations, and FIC1 disease, 535–544
Autoimmune hepatitis, de novo, in pediatric patient, 573–578
Autoimmunity, and biliary atresia, 517–524

B
Bile, formation of, CFTR and, 471–488
Bile ducts, extrahepatic, perforation of, imaging of, in pediatric patient, 251–269
Bile leaks, postoperative, scintigraphy of, 179–194
Bile salt export pump (BSEP)
  function of, 545–550
  in progressive familial intrahepatic cholestasis, 545–550
Biliary atresia
  etiopathogenesis of, 517–524
  imaging of, 251–269
Biliary dyskinesia, scintigraphy in, 179–194
Biliary obstruction, scintigraphy in, 179–194
Biliary secretion, regulation of, 471–488
Blood flow, hepatic, regulation of, hepatic stellate cells in, 337–349
Book review
  Hepatitis C. Biomedical Research Reports (Liang and Hoofnagle, eds.), 297
  Liver Biopsy Interpretation, 6th ed. (Scheuer and Lefkowitch), 579
Budd-Chiari syndrome, hepatic imaging in, 161–177, 195–212

C
Candidiasis, hepatic imaging in, 195–212
Cat-scratch disease, in pediatric patient, hepatic imaging in, 251–269
Celiac disease, steatohepatitis in, 27–41
Chemoembolization, for liver tumors, 283–291
Chemokines, in hepatic stellate cell biology, 397–416
Cholangiocarcinoma, imaging of, 161–177, 179–194
Cholecystitis, calculous and acalculous, scintigraphy in, 179–194
Choledochal cyst, imaging of, 251–269
Cholestasis. *See also* Familial intrahepatic cholestasis
  drug-induced, and MDR3 deficiency, 551–562
  intrahepatic, of pregnancy, and MDR3 deficiency, 551–562
  neonatal, 517–524, 525–534
    in cystic fibrosis, 471–488
    transient, and MDR3 deficiency, 551–562
Cirrhosis
  adult "idiopathic," and MDR3 deficiency, 551–562
  biliary, in cystic fibrosis, 471–488
  hepatic imaging in, 161–177, 213–224
  multilobular, in cystic fibrosis, 471–488
  in nonalcoholic fatty liver, 17–26
  screening methods in, 213–224
Collagen, in hepatic fibrosis, 351–372, 427–436, 437–451
Computed tomography (CT)
  of benign hepatic masses, 237–249
  in cirrhotic liver, 213–224
  contrast enhancement in, 135–145
  in diffuse liver disease, 195–212
  in hepatic steatosis, 71–80
  in metastatic disease of liver, 225–236
  in pediatric patient, 251–269
  principles and rationale for, 135–145
  for right lobe living donor liver transplantation, 271–282
  techniques of, 135–145
Congenital disorders of glycosylation
  biochemistry of, 501–515
  laboratory diagnosis of, 501–515
  signs of, 501–515
  treatment of, 501–515
  types of, 501–515

Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Coralgil, steatohepatitis caused by, 27–41
Cryoablation, for liver tumors, 283–291
Cyst(s), hepatic, imaging of, 237–249
  in pediatric patient, 251–269
Cystadenoma, biliary, imaging of, 237–249
Cystic fibrosis, liver disease in
  clinical manifestations of, 471–488
  pathogenesis of, 471–488
  treatment of, 471–488
Cystic fibrosis transmembrane conductance regulator
  function of, in biliary epithelium, 471–488
  mutations of, 471–488
Cytokines
  in hepatic stellate cell biology, 373–384, 397–416, 417–426
  and steatohepatitis, 57–69

D
Diabetes mellitus, and steatohepatitis, 17–26, 27–41
Diet, and steatosis, animal models of, 89–104
Diethylaminoethoxyhexestrol, steatohepatitis caused by, 57–69
Dysplastic nodules
  imaging of, 213–224
  pathology of, 213–224

E
Endothelin, in hepatic stellate cell biology, 337–349, 397–416
Erythrocytes, technetium-99m–labeled, in hepatobiliary scintigraphy, 179–194
Estrogen receptor ligands, and steatohepatitis, 27–41
Estrogens, and steatohepatitis, 27–41, 89–104
Ethanol ablation, for liver tumors, 283–291
Etomoxir, and steatosis, 89–104
Extracellular matrix, hepatic
  in hepatic fibrinogenesis, 351–372
  hepatic stellate cells and, 311–335, 351–372, 373–384
  organization of, 351–372

F
Familial intrahepatic cholestasis
  progressive
    BSEP in, 545–550
    genetics of, 545–550
    type 3, 551–562
  type 1 (FIC1 disease), 535–544
Fas ligand, and steatohepatitis, 57–69
Fatty acid transport and mitochondrial oxidation, inborn errors of
  clinical manifestations of, 489–500
  laboratory diagnosis of, 489–500
  pathophysiology of, 489–500
Fatty acyl-CoA oxidase deficiency, peroxisomal, 43–55
Fatty infiltration of liver, magnetic resonance imaging in, 161–177
Fatty liver. *See* Nonalcoholic fatty liver (NAFL); Steatohepatitis; Steatosis
Fibrinogenesis, hepatic
  extracellular matrix in, 351–372
  immune cell modulation and, 417–426
Fibrosis, hepatic
  in cirrhosis, 213–224
  in nonalcoholic fatty liver, risk factors for, 17–26
  in nonalcoholic steatohepatitis, 3–16
  progression and regression of, MMPs and TIMPs in, 373–384, 427–436
  stellate cells in, 373–384, 427–436
  treatment of, stellate cells as target in, 437–451
FIC1 disease
  clinical course of, 535–544
  clinical presentation of, 535–544
  genetics of, 535–544
  treatment of, 535–544
FIC1 protein
  functions of, 535–544
  molecular biology of, 535–544
Focal nodular hyperplasia, imaging of, 147–159, 161–177, 179–194, 237–249
  in pediatric patient, 251–269

G
Gallium-67, in hepatobiliary scintigraphy, 179–194
Gallstone disease, and MDR3 deficiency, 551–562
Gastroplasty, and nonalcoholic steatohepatitis, 27–41
Growth factors, polypeptide, in hepatic stellate cell biology, 397–416

H
Hamartomas
  bile duct, imaging of, 195–212, 237–249
  mesenchymal, in pediatric patient, imaging of, 251–269
Heart failure, passive hepatic congestion in, imaging in, 195–212
Hemangioendothelioma, in pediatric patient, imaging of, 251–269
Hemangioma, hepatic, imaging of, 147–159, 161–177, 179–194, 237–249
  in pediatric patient, 251–269
Hemochromatosis, primary, imaging in, 195–212
Hemosiderosis, imaging in, 195–212
Hepatitis
  hepatic imaging in, 195–212
  neonatal, imaging of, 251–269
Hepatitis C, chronic, in pediatric patient, 573–578
Hepatoblastoma, in pediatric patient, imaging of, 251–269
Hepatocellular alterations, in steatosis, 3–16, 105–113
Hepatocellular carcinoma (HCC)
  epidemiology of, 213–224
  fibrolamellar, in pediatric patient, imaging of, 251–269
  imaging of, 147–159, 161–177, 179–194, 195–212, 213–224
    in pediatric patient, 251–269
  pathology of, 213–224
  treatment of, minimally invasive techniques for, 283–291
Hepatotoxicity, occupational, 27–41
Hereditary tyrosinemia type 1. *See* Tyrosinemia, hepatorenal
Hyperlipidemia, and nonalcoholic steatohepatitis, 27–41
Hypertyrosinemia, differential diagnosis of, 563–571

I
Imaging, hepatic
  advances in, 133
  with benign hepatic masses, 237–249

in cirrhosis, 213–224
in cystic fibrosis, 471–488
in diffuse liver disease, 195–212
for guidance, in treatment of liver tumors, 283–291
in metastatic disease, 225–236
in pediatric patient, 251–269
for right lobe living donor liver transplantation, 271–282
in steatosis, 71–80
Immune cells, and stellate cells, interactions of, 417–426
Immune response, and biliary atresia, 517–524
Inflammation, hepatic
in nonalcoholic steatohepatitis, 3–16
suppression of, 437–451
Insulin, and steatosis, 27–41, 89–104
Integrin signaling, in hepatic stellate cell biology, 397–416
Iron overload, hepatic imaging in, 161–177, 195–212
Iron storage disorders, and nonalcoholic steatohepatitis, 3–16, 27–41
Ischemia-reperfusion injury, in steatotic liver, 105–113

J
Jagged1 *(JAG1)* gene, in Alagille syndrome, 525–534
Jaundice, neonatal, hepatic imaging in, 251–269
Jejunoilial bypass, and steatohepatitis, 27–41, 57–69

L
Laser ablation, for liver tumors, 283–291
Leptin, and steatosis, 89–104
Leukocytes, and stellate cells, interactions of, 417–426
Levovist, postvascular scans with, in hepatic imaging, 147–159
Lipids, peroxidation, and steatohepatitis, 57–69, 89–104
Lipoma, hepatic, imaging of, 237–249
Liver
diffuse disease of, imaging of, 161–177, 195–212
failure of, fatty acid transport and mitochondrial oxidation disorders and, 489–500
injury, recovery from, stellate cells in, 373–384, 427–436
regeneration, MMPs and TIMPs in, 373–384
surgery on, steatosis and, 105–113
transplantation of
for cystic fibrosis liver disease, 471–488
postoperative scintigraphy in, 179–194
right lobe living donor, imaging for, 271–282
steatosis and, 105–113
Long-chain fatty acid transport/binding defects, and liver failure, 489–500
Lymphangioma, hepatic, imaging of, 237–249
Lymphoma, hepatic imaging in, 195–212

M
Magnetic resonance imaging (MRI)
of benign hepatic masses, 237–249
in cirrhotic liver, 213–224
contrast agents for, 161–177
in diffuse liver disease, 195–212
ferumoxide-enhanced, 161–177
gadolinium-enhanced, 161–177
in hepatic steatosis, 71–80
manganese DPDP (mangafodipir trisodium)-enhanced, 161–177
in metastatic disease of liver, 225–236
in pediatric patient, 251–269
in right lobe living donor liver transplantation, 271–282
T1-weighted, 161–177
T2-weighted, 161–177
Magnetic resonance spectroscopy, chemical shift, in hepatic steatosis, 71–80
Matrix metalloproteinase (MMP), and extracellular matrix, 351–372, 373–384, 427–436
Medium- and short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency, and liver failure, 489–500
Metastases, to liver
evaluation for, 225–236
imaging of, 147–159, 179–194, 195–212
in pediatric patient, 251–269
treatment of, minimally invasive techniques for, 283–291
Metformin, effects in *ob/ob* mice, 57–69
Methotrexate, steatohepatitis caused by, 27–41
Mice
genetically modified, hepatic pathophysiology in, 43–55, 57–69, 89–104
mdr2 knockout, 551–562
ob/ob, 57–69, 89–104
Microabscesses, fungal, in pediatric patient, imaging of, 251–269
Mitochondria, in steatohepatitis, 43–55, 57–69, 89–104
Multidrug resistance 3 deficiency
in liver disease, 551–562
treatment of, 551–562
Myelolipoma, hepatic, imaging of, 237–249
Myofibroblasts, in hepatic fibrogenesis, 351–372

N
Neonatal cholestasis, scintigraphy in, 179–194
Neoplasms, hepatic
benign
imaging of, 161–177, 179–194, 237–249
versus malignant, positron emission tomography of, 179–194
in pediatric patient, imaging of, 251–269
lipomatous, imaging of, 237–249
malignant, in pediatric patient, imaging of, 251–269
in pediatric patient, imaging of, 251–269
treatment of, minimally invasive techniques for, 283–291
Nitric oxide, and stellate cell contractility, 337–349
Nonalcoholic fatty liver (NAFL), 1–2
classification of, 17–26
clinical features of, 17–26
etiology of, 81–88
fibrosis in, risk factors for, 17–26
natural history of, 17–26
prevalence of, 17–26
treatment of, 81–88
Nonalcoholic steatohepatitis (NASH), 1–2. *See also* Steatohepatitis
clinical features of, 17–26
comorbid conditions with, 3–16
definition of, 3–16
diagnosis of, histologic criteria for, 3–16
etiology of, 27–41
fibrogenesis in, 27–41

Nonalcoholic steatohepatitis (NASH) *(continued)*
histologic evaluation in, criteria for, 3–16
histologic lesions of
grading of, 3–16
staging of, 3–16
imaging in, 71–80
microscopic findings in, 3–16
natural history of, 17–26
pathogenesis of, 27–41
pathology of, 3–16
terminology for, 3–16
vs. alcoholic hepatitis, 17–26

O
Obesity, and steatohepatitis, 17–26, 27–41, 57–69
animal models of, 89–104
β-Oxidation
mitochondrial, 43–55
peroxisomal
deficiency, human diseases of, 43–55
and steatohepatitis, 43–55
ω-Oxidation, mitochondrial, 43–55
Oxidative stress, and nonalcoholic steatohepatitis, 27–41

P
Pediatric hepatology, advances in, 469–470
Perhexiline, steatohepatitis caused by, 27–41, 57–69
Peroxisome proliferator activator receptor(s) (PPAR)
and nonalcoholic steatohepatitis, 27–41, 43–55
in stellate cell activation, 385–395
Polycystic liver disease, imaging in, 195–212
Porphyria cutanea tarda, in alcoholic liver disease, 119–128
Portal hypertension
in cirrhosis, 213–224
pathogenesis of, hepatic stellate cells in, 337–349
Portal vein thrombosis, magnetic resonance imaging in, 161–177
Positron emission tomography (PET), of hepatobiliary system, 179–194
Posttransplant lymphoproliferative disorder, in pediatric patient, imaging of, 251–269
Progesterone, and liver adenomatosis, 453–459
Proteins, N-glycosylation of, 501–515
Pseudoalcoholic liver disease, 119–128

R
Radiocolloids, in hepatobiliary scintigraphy, 179–194
Radio-frequency ablation, for liver tumors, 283–291
Radionuclide imaging, hepatobiliary, 179–194
Radiopharmaceuticals, 179–194
Rats, *fa/fa*, 89–104
Reactive oxygen species, in steatohepatitis, 57–69
Regenerative nodules, imaging of, 161–177, 213–224, 237–249

S
Sarcoidosis, hepatic imaging in, 195–212, 283–291
Sarcoma, undifferentiated (embryonal), in pediatric patient, imaging of, 251–269
Schistosomiasis, hepatic imaging in, 195–212
Sedation, for CT and MRI, in pediatric patient, 251–269
Sinusoidal blood flow, regulation of, hepatic stellate cells and, 311–335, 337–349
Sphincter of Oddi spasm, scintigraphy in, 179–194
Steatohepatitis. *See also* Nonalcoholic steatohepatitis (NASH)
alcoholic, pathophysiology of, 57–69
clinical management of, 57–69
drug-induced, 27–41, 57–69
genetics of, 27–41, 57–69
mitochondria in, 43–55, 57–69
peroxisomal β-oxidation and, 43–55
primary, pathophysiology of, 57–69
reactive oxygen species and, 57–69
secondary, pathophysiology of, 57–69
in Weber-Christian disease, 115–118
Steatosis
focal sparing in, imaging of, 195–212
hepatic
animal models of, 89–104
in cystic fibrosis, 471–488
diffuse, imaging in, 195–212
focal, imaging in, 195–212, 237–249
imaging in, 71–80, 195–212
and liver surgery, 105–113
and liver transplantation, 105–113
in steatohepatitis, 3–16, 57–69
Stellate cells
extrahepatic, 311–335
hepatic, 307–309
apoptosis, 427–436
contractility of, 337–349
cytokine receptors and signaling in, 373–384, 397–416
developmental biology of, 311–335
and extracellular matrix, 311–335, 351–372
in extracellular matrix degradation, 311–335, 373–384
functions of, 311–335, 337–349
in hepatic fibrogenesis, 351–372
heterogeneity of, 311–335
interactions with immune system, 417–426
life cycle of, 311–335
localization of, 311–335
morphology of, 311–335
quiescent, 311–335
in recovery from liver injury, 427–436
targeting, in antifibrotic therapy, 437–451
transcriptional regulation in, 311–335, 385–395
visualization of, 311–335

T
Tamoxifen, steatohepatitis caused by, 57–69
Technetium-99m iminodiacetic acid, in hepatobiliary scintigraphy, 179–194
Tissue inhibitor of metalloproteinases, in hepatic stellate cells, 351–372, 373–384, 427–436
Total parenteral nutrition, and steatohepatitis, 27–41, 57–69
Transcriptional regulation, in hepatic stellate cells, 311–335, 385–395
Transforming growth factor-β receptor superfamily, in hepatic stellate cell biology, 397–416
Tuberculosis, hepatic imaging in, 195–212
Tumor necrosis factor receptor superfamily, in hepatic stellate cell biology, 397–416, 427–436

Tumors. *See* Neoplasms, hepatic
Tyrosinemia, hepatorenal
  differential diagnosis of, 563–571
  pathophysiology of, 563–571
  treatment of, 563–571

U
Ultrasound, hepatic
  in cirrhosis, 213–224
  in diffuse liver disease, 195–212
  in hepatic steatosis, 71–80
  intraoperative, in right lobe living donor liver transplantation, 271–282
  of liver mass, 147–159
  in metastatic disease, 225–236
  microbubble contrast agents in, 147–159
  in pediatric patient, 251–269
  pulse inversion imaging in, 147–159
Uncoupling protein 2, and steatohepatitis, 57–69
Ursodeoxycholic acid, for cystic fibrosis liver disease, 471–488

V
Veno-occlusive disease, hepatic, imaging in, 195–212
Viruses, and biliary atresia, 517–524
Vitamin A, homeostasis, hepatic stellate cells and, 311–335

W
Weber-Christian disease, hepatic involvement in, 115–118
Weight loss, rapid, and steatohepatitis, 27–41, 57–69
Wilson's disease
  hepatic imaging in, 195–212
  steatohepatitis in, 27–41, 57–69